Please assess the completion status of the following clinical trial:

Trial Title: Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* male and female~* 18 - 64 years~* written informed consent~* physical exam: no abnormal findings unless considered irrelevant by the investigator~* uneventful medical history~* females: adequate contraception~Exclusion Criteria:~* pregnancy~* positive virology markers at first screening~* signs and symptoms of relevant autoimmunity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Dose Group 1 (Type: EXPERIMENTAL): Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
- Dose Group 2 (Type: EXPERIMENTAL): Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
- Dose Group 3 (Type: EXPERIMENTAL): Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
- Dose Group 0 (Type: PLACEBO_COMPARATOR): Control: Al(OH)3 Adjuvant

Based on this trial design, predict the completion outcome and termination type (if applicable).